NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition

Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues

(2019) Donglu Zhang et al.   DRUG METABOLISM AND DISPOSITION

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

(2018) Francesca Zammarchi et al.   BLOOD

An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia

(2018) Bing Zheng et al.   CLINICAL CANCER RESEARCH

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

(2018) Tycel Phillips et al.   INVESTIGATIONAL NEW DRUGS

From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)

(2016) Julia Mantaj et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody–Drug Conjugates

(2016) Donglu Zhang et al.   ACS Medicinal Chemistry Letters

What Are the Potential Sites of Protein Arylation by N-Acetyl-p-benzoquinone Imine (NAPQI)?

(2015) Michael G. Leeming et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Mechanism-based inactivation of cytochrome P450 2B6 by isoimperatorin

(2015) Jiaojiao Cao et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Synthetic modified pyrrolo[1,4] benzodiazepine molecules demonstrate selective anticancer activity by targeting the human ligase 1 enzyme: An in silico and in vitro mechanistic study

(2015) Mohammad Shameem et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Mechanism-based inactivation of cytochrome P450 2B6 by isopsoralen

(2015) Dan Lu et al.   XENOBIOTICA

Pyrrolo[2,1-c][1,4]benzodiazepine as a Scaffold for the Design and Synthesis of Anti- Tumour Drugs

(2012) Laura Cipolla et al.   Anti-Cancer Agents in Medicinal Chemistry

An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes

(2011) A. Parkinson et al.   DRUG METABOLISM AND DISPOSITION

The development of pyrrolobenzodiazepines as antitumour agents

(2011) John A Hartley   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats

(2010) Joel M. Reid et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Characterization of HKI-272 Covalent Binding to Human Serum Albumin

(2010) J. Wang et al.   DRUG METABOLISM AND DISPOSITION

Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6

(2009) Sui-Lin Mo et al.   CURRENT DRUG METABOLISM

CYP2B6: New Insights into a Historically Overlooked Cytochrome P450 Isozyme

(2008) Hongbing Wang et al.   CURRENT DRUG METABOLISM

Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78

(2008) M. Kotecha et al.   MOLECULAR CANCER THERAPEUTICS

Mechanism-Based Inactivation of Human Cytochromes P450s: Experimental Characterization, Reactive Intermediates, and Clinical Implications

(2007) Paul F. Hollenberg et al.   CHEMICAL RESEARCH IN TOXICOLOGY